The Scientist

» industry and immunology

Most Recent

image: B Cells Can Drive Inflammation in MS

B Cells Can Drive Inflammation in MS

By | October 21, 2015

Researchers identify a subset of proinflammatory cytokine-producing B cells that may spark multiple sclerosis-related inflammation.  

0 Comments

image: Two-Faced Proteins May Tackle HIV Reservoirs

Two-Faced Proteins May Tackle HIV Reservoirs

By | October 21, 2015

Researchers design antibody-like proteins to awaken and destroy HIV holdouts.

0 Comments

image: Teva Buys Mexican Pharma Firm

Teva Buys Mexican Pharma Firm

By | October 5, 2015

The Israeli drugmaker is purchasing the pharmaceutical company Rimsa for $2.3 billion.

0 Comments

image: Treating Toxoplasmosis

Treating Toxoplasmosis

By | September 25, 2015

While one company hikes the price of an old drug to treat the parasitic infection, academic researchers report that an approved blood pressure medication could be just what the doctor ordered.

4 Comments

image: Dengue’s Downfall?

Dengue’s Downfall?

By | September 15, 2015

Researchers characterize a protein that could be key to the virus’s virulence—and to developing a vaccine against the mosquito-borne disease.

0 Comments

image: Using FOIA to Read Scientists’ Emails

Using FOIA to Read Scientists’ Emails

By | September 8, 2015

Journalists and activists use the Freedom of Information Act to expose academics’ relationships with industry.

2 Comments

image: Immune Cells Can Deliver Deadly Packages

Immune Cells Can Deliver Deadly Packages

By | September 8, 2015

Much of the CD4+ T-cell death that occurs during HIV infection may be caused by direct delivery of the virus from neighboring cells, a study shows.

0 Comments

image: TS Picks: September 8, 2015

TS Picks: September 8, 2015

By | September 8, 2015

Pharma edition

0 Comments

image: Body, Heal Thyself

Body, Heal Thyself

By | September 1, 2015

Reviving a decades-old hypothesis of autoimmunity

8 Comments

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

3 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech